was supported by the Alexander von Humboldt fellowship
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes mellitus and, more recently, obesity
GLP-1s should not replace tried-and-true ADHD assessments and treatments
have shown that elevated levels of serum ammonia and myostatin contribute to sarcopenia in cirrhosis.21 And so a vicious circle is formed when a cirrhotic patient develops sarcopenia, given that there is a decrease in the elimination of ammonia in sarcopenic patients, which in turn, leads to a higher risk for developing hyperammonemia and HE.22 The detoxification of ammonia through the administration of L-ornithine L-aspartate (LOLA) in a murine model of sarcopenia and steatohepatitis significantly improved mean body mass, hand grip strength, and mean diameter of muscle fiber, in the group supplemented with LOLA vs
the clinical significance of reducing IGFBP engagement through synthetic analogues is not yet resolved [9]
1 summarises these metabolic effects in humans [8,16]
